Ecstasy vs Molly: What's Actually in Pressed Pills
Ecstasy is pressed tablets, molly is powder, and neither word is a purity claim. What drug checking finds in both, and how to test before you take it.
May 15, 2026 · Jordan Mercer
Contents
“Ecstasy” means pressed pills and “molly” means powder, and neither word tells you anything about what is in your hand. In some markets powder is cut more often than pills, not less. The only real difference is that a tablet has a fixed dose you can at least characterise, while powder has to be weighed. Treating “molly” as a purity claim is one of the most common mistakes people make before taking MDMA.
| Ecstasy | Molly | |
|---|---|---|
| Form | Pressed pills or tablets | Powder or crystal |
| Supposed to be | MDMA | MDMA |
| Purity | Not guaranteed | Not guaranteed, often cut more rather than less |
| Dose certainty | Fixed per tablet, but tablets range from 0 to over 300 mg | Requires accurate weighing |
| Common adulterants | Cathinones, meth, caffeine, PMA/PMMA, DXM | Cathinones and other NPS at similar rates |
| How to verify | Marquis, Simon’s and Mecke, plus a fentanyl strip | Same |
Where the two words came from
The split became common in the US around 2008. “Molly,” short for molecular, was supposed to signal pure MDMA, while pills carried the reputation for being cut. Testing data has never supported that.
Palamar and colleagues documented in Substance Abuse in 2016 that molly is marketed as pure MDMA while being frequently adulterated with synthetic cathinones and other novel psychoactive substances, to the point that the name stopped describing the contents. A 25-year analysis of EcstasyData and DrugsData submissions found the same thing from the other direction: the relationship between form and purity is unreliable, and both are routinely misrepresented.
What has actually turned up in pills
Drug checking data from DrugsData and DanceSafe programs between 1999 and 2023 shows the adulterant mix shifting over time, but the recurring cast is small enough to list.
- Synthetic cathinones. Methylone, pentylone, N-ethyl pentylone. The dominant class of the past decade. Effects can resemble MDMA at first, with different duration, toxicity and risk.
- Amphetamine and methamphetamine. Stimulation with a far longer duration, more cardiovascular load and higher addiction potential.
- Caffeine. Historically the most common padding. Little direct harm, but it tells you the pill is being stretched.
- Piperazines, BZP and mCPP, sold as legal alternatives around 2009 to 2013. Anxiety, seizures, and a bad night at higher doses.
- DXM. Common in the early-2000s US market. A dissociative, unpredictable at ecstasy doses.
- PMA and PMMA. Rare and high-risk. Slower onset than MDMA, so people redose thinking nothing happened, against a narrow margin. Linked to multiple deaths.
- Fentanyl. Detected in some MDMA samples, less often than in the opioid or cocaine supply, but the spread of fentanyl into the stimulant supply generally is documented.
- Nothing active at all. Some pills are filler.
That same 25-year analysis counted 199 unique adulterants in samples sold as MDMA, and more than half of submitted samples were misrepresented in some way. No list is going to be complete.
N-ethyl pentylone is the one to worry about
Also called ephylone, it has turned up in pressed tablets across the US, UK, Australia and South Africa, and it is significantly more potent than MDMA by weight. A tablet pressed to a normal ecstasy weight therefore holds a large relative dose of it.
What makes it dangerous is the shape of the experience:
- The first effects resemble MDMA closely enough that most people don’t realise anything is wrong.
- The empathogenic peak fades faster than MDMA’s, so it feels like the drug wore off early.
- The stimulant part does not fade. Community reports describe being unable to sleep for 36 hours or more without any redose at all.
- People redose, because they think the first one failed. Each one adds stimulant load without returning the warmth they were chasing.
The endpoint is stimulant toxicity: tachycardia, hyperthermia, agitation, paranoia, hallucinations, and in severe cases death. Forensic toxicology case reports have linked multiple fatalities to it.
The useful part: N-ethyl pentylone does not give MDMA’s reagent results. A Marquis test catches this substitution.
Identical pills, wildly different doses
Morefield and colleagues, publishing in Addiction in 2011, analysed pill content alongside the plasma concentrations that resulted and confirmed that appearance predicts nothing. Same logo, same colour, same size, dramatically different MDMA content.
European pill monitoring shows average content climbing, with some tablets over 300 mg. A 300 mg pill is two to three times a moderate recreational dose. Swallowing a whole one on the assumption it holds a normal dose, then redosing at 45 minutes because nothing has happened yet, is the standard route into an emergency department.
Half a pill, then wait 90 minutes is the minimum precaution with any tablet you have not had lab tested.
Molly is not purer, and there is data
The powder-is-purer idea persists because it sounds sensible. No pressing step, no binder needed to hold a shape.
In practice the reverse can hold. Any white or off-white powder mixes into another one invisibly, whereas pressing tablets takes a press and a mould, which some suppliers treat as a reason to protect their product’s reputation. DanceSafe’s own drug checking analysis found no evidence that powder is less likely to be adulterated than pills, and Saleemi and colleagues, writing in the Journal of Psychopharmacology in 2017, found products sold as molly at raves contained non-MDMA substances at rates comparable to ecstasy tablets.
The form tells you nothing. Testing tells you something.
Testing a pill
Pills have one advantage over powder here: scraping gives you a clean surface to read the colour against. Take a match-head sized scraping for each reagent, on a white ceramic surface.
Marquis first. One or two drops on the scraping, watch for 30 to 60 seconds. MDMA goes purple to black. Methamphetamine and amphetamine go orange to brown. Orange, yellow or no reaction means no MDMA, and that is where you stop. Do not take it.
Simon’s separates MDMA from MDA. MDMA turns blue, MDA does not change. MDA lasts longer and behaves differently, so which one you have changes your dosing.
Mecke confirms. MDMA goes blue-green to black, and Mecke catches some cathinones that Marquis can miss in a mixed sample.
Fentanyl strips. Dissolve a pill fragment in water at 2 teaspoons (10 mL) per 10 mg of material, which is the dilution that stops MDMA itself triggering a false positive. Dip 15 seconds, read at 2 to 5 minutes. One line is POSITIVE, fentanyl detected, do not use it. Two lines is NEGATIVE. That reading is backwards from what nearly everyone assumes, so check it twice.
Full protocol in the test kit guide, and the MDMA-specific dilution detail in the fentanyl test strip guide.
If you’re going to take it
Testing narrows the field. It does not certify a dose or a purity, so the rest still applies.
Start with half a pill and wait a full 90 minutes before deciding anything. MDMA peaks later than people expect, and later still on a full stomach.
If it feels wrong, too much stimulation, not enough warmth, or a peak that fades fast and leaves you wired, treat that as a probable cathinone and do not redose. The stimulant effects can run for many hours regardless of what you do next.
Keep alcohol and other substances out of it, particularly if the reagent result was ambiguous. Check the interaction checker for specific combinations. Drink 250 to 500 mL of water an hour if you’re dancing and less if you’re not. Have naloxone within reach even at an MDMA event, because fentanyl in MDMA is rare and the cost of meeting it without naloxone nearby is not.
And tell someone what you took. If the night goes wrong, that is the single most useful thing anyone around you can know.
For dosing, supplements, interactions and the comedown, see the MDMA guide.
Sources
PMID 39437494 | PMID 37826988 | PMID 21320226 | PMID 28693371